{
    "id": 8876,
    "fullName": "RAF1 P261A",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RAF1 P261A lies within the CR2 domain of the Raf1 protein (PMID: 17603482, PMID: 17603483). P261A confers a gain of function to the Raf1 protein as demonstrated by increased Raf kinase activity, downstream Mek and Erk phosphorylation (PMID: 17603482), is transforming in cell culture (PMID: 31285551) and resistant to type I Raf inhibitors (PMID: 31285551).",
            "references": [
                {
                    "id": 494,
                    "pubMedId": 17603482,
                    "title": "Germline gain-of-function mutations in RAF1 cause Noonan syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17603482"
                },
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                },
                {
                    "id": 3187,
                    "pubMedId": 17603483,
                    "title": "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17603483"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5894,
        "geneSymbol": "RAF1",
        "terms": [
            "RAF1",
            "c-Raf",
            "CMD1NN",
            "CRAF",
            "NS5",
            "Raf-1"
        ]
    },
    "variant": "P261A",
    "createDate": "07/09/2015",
    "updateDate": "07/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 161816,
        "transcript": "NM_002880",
        "gDna": "chr3:g.12604189G>C",
        "cDna": "c.781C>G",
        "protein": "p.P261A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17577,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A was resistant to Tafinlar (dabrafenib), as demonstrated by increased cell viability and elevated Erk phosphorylation in culture (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17580,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A demonstrated sensitivity to LY3009120 resulting in decreased phosphorylation of Erk in culture and decreased cell viability (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17581,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A demonstrated sensitivity to AZ628 resulting in decreased phosphorylation of Erk in culture and decreased cell viability (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17579,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A was resistant to Nexavar (sorafenib), as demonstrated by increased cell viability and elevated Erk phosphorylation in culture (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17578,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A was resistant to Zelboraf (vemurafenib), as demonstrated by increased cell viability and elevated Erk phosphorylation in culture (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A demonstrated enhanced sensitivity to the combination of Mekinist (trametinib) and LY3009120, resulting in decreased phosphorylation of Erk in culture and decreased cell viability (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 8557,
                "therapyName": "LY3009120 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8770,
            "profileName": "RAF1 P261A",
            "profileTreatmentApproaches": [
                {
                    "id": 18434,
                    "name": "Trametinib",
                    "profileName": "RAF1 P261A"
                },
                {
                    "id": 18433,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "RAF1 P261A"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 161818,
            "transcript": "XM_005265355",
            "gDna": "chr3:g.12604189G>C",
            "cDna": "c.781C>G",
            "protein": "p.P261A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 161816,
            "transcript": "NM_002880",
            "gDna": "chr3:g.12604189G>C",
            "cDna": "c.781C>G",
            "protein": "p.P261A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 161817,
            "transcript": "XM_011533974",
            "gDna": "chr3:g.12604189G>C",
            "cDna": "c.781C>G",
            "protein": "p.P261A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}